Inside HDACs with more selective HDAC inhibitors

European Journal of Medicinal Chemistry

Volumn 121, Issue , 2016, Pages 451-483

  Roche, Joëlle ^a,c   Bertrand, Philippe ^b,c  

^a UNIVERSITÉ DE POITIERS   (France)

^b UMR   (France)

^c Reseau Epigenetique du Canceropole Grand Ouest   (France)

Author keywords

Epigenetics; HDAC inhibitors; Histone acetylation; Molecular modelling; Synthesis

Indexed keywords

ANDROGEN RECEPTOR; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE; BETA CYCLODEXTRIN; CARBONATE DEHYDRATASE; CARBOXYLIC ACID; CYCLOPEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DNA TOPOISOMERASE; ENTINOSTAT; ESTROGEN RECEPTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LYSINE; MATRIX METALLOPROTEINASE; MONOPHENOL MONOOXYGENASE; VORINOSTAT; ZINC BINDING PROTEIN; ORGANIC COMPOUND;

ADAPTIVE IMMUNITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; CANCER CELL LINE; CYTOSKELETON; DEACETYLATION; DEGRADATION; DRUG ACTIVITY; DRUG STABILITY; DRUG STRUCTURE; ENTHALPY; ENTROPY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME STRUCTURE; GENE LOCATION; HUMAN; IC50; INNATE IMMUNITY; ISOTOPE LABELING; MICROTUBULE; MITOSIS; MOLECULAR BIOLOGY; MUTAGENESIS; NONHUMAN; PLEIOTROPY; POLYMERIZATION; PROTEIN LOCALIZATION; REVIEW; SCHISTOSOMIASIS; ANIMAL; CHEMISTRY; ENZYME SPECIFICITY; METABOLISM;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; ORGANIC CHEMICALS; SUBSTRATE SPECIFICITY;

EID: 84974674596     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: None     Document Type: Review

References (178)

1. H. Heyn, M. Esteller, DNA methylation profiling in the clinic: applications and challenges, Nat. Rev. Genet. 13 (2012) 679, http://dx.doi.org/10.1038/nrg3270.
2. K.D. Meyer, Y. Saletore, P. Zumbo, O. Elemento, C.E. Mason, S.R. Jaffrey, Comprehensive analysis of mRNA methylation reveals enrichment in 30 UTRs and near stop codons, Cell. 149 (2012) 1635, http://dx.doi.org/10.1016/j.cell.2012.05.003.
3. G.E. Zentner, S. Henikoff, Regulation of nucleosome dynamics by histone modifications, Nat. Struct. Mol. Biol. 20 (2013) 259, http://dx.doi.org/10.1038/nsmb.2470.
4. T.R. Mercer, J.S. Mattick, Structure and function of long noncoding RNAs in epigenetic regulation, Nat. Struct. Mol. Biol. 20 (2013) 300, http://dx.doi.org/10.1038/nsmb.2480.
5. A. Chandran, C. Antony, L. Jose, S. Mundayoor, K. Natarajan, R.A. Kumar, Mycobacterium tuberculosis infection induces HDAC1-mediated suppression of IL-12B gene expression in macrophages, Front. Cell. Infect. Microbiol. 5 (2015) 90, http://dx.doi.org/10.3389/fcimb.2015.00090.
6. M. Lauria, V. Rossi, Epigenetic control of gene regulation in plants, Biochim. Biophys. Acta BBA e Gene Regul. Mech. 1809 (2011) 369, http://dx.doi.org/10.1016/j.bbagrm.2011.03.002.
7. B.A. Wyse, R. Oshidari, D.C. Jeffery, K.Y. Yankulov, Parasite epigenetics and immune evasion: lessons from budding yeast, Epigenetics Chromatin. 6 (2013) 1, http://dx.doi.org/10.1186/1756-8935-6-40.
8. J. Beau, N. Mahid, W.N. Burda, L. Harrington, L.N. Shaw, T. Mutka, et al., Epigenetic tailoring for the production of anti-infective cytosporones from the marine fungus Leucostoma persoonii, Mar. Drugs 10 (2012) 762, http://dx.doi.org/10.3390/md10040762.
9. S. Rousseaux, S. Khochbin, Histone acylation beyond acetylation: terra incognita in chromatin biology, Cell J. Yakhteh 17 (2015) 1.
10. I.A. Hendriks, R.C. D'Souza, B. Yang, M. Verlaan-de Vries, M. Mann, A.C. Vertegaal, Uncovering global SUMOylation signaling networks in a sitespecific manner, Nat. Struct. Mol. Biol. 21 (2014) 927, http://dx.doi.org/10.1038/nsmb.2890.
11. C. Chatterjee, R.K. McGinty, J.-P. Pellois, T.W. Muir, Auxiliary-mediated sitespecific peptide ubiquitylation, Angew. Chem. Int. Ed. 46 (2007) 2814, http://dx.doi.org/10.1002/anie.200605155.
12. M.O. Hottiger, Nuclear ADP-ribosylation and its role in chromatin plasticity, cell differentiation, epigenetics, Annu. Rev. Biochem. 84 (2015) 227, http://dx.doi.org/10.1146/annurev-biochem-060614-034506.
13. K. Sakabe, Z. Wang, G.W. Hart, b-N-acetylglucosamine (O-GlcNAc) is part of the histone code, Proc. Natl. Acad. Sci. 107 (2010) 19915, http://dx.doi.org/10.1073/pnas.1009023107.
14. M. Mottamal, S. Zheng, T.L. Huang, G. Wang, Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents, Molecules 20 (2015) 3898, http://dx.doi.org/10.3390/molecules20033898.
15. M. Duvic, J. Vu, Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma, Expert Opin. Investig. Drugs 16 (2007) 1111, http://dx.doi.org/10.1517/13543784.16.7.1111.
16. C. Grant, F. Rahman, R. Piekarz, C. Peer, R. Frye, R.W. Robey, et al., Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors, Expert Rev. Anticancer Ther. 10 (2010) 997, http://dx.doi.org/10.1586/era.10.88.
17. R. Poole, Belinostat: first global approval, Drugs 74 (2014) 1543, http://dx.doi.org/10.1007/s40265-014-0275-8.
18. M.P. Fenichel, FDA approves new agent for multiple myeloma, J. Natl. Cancer Inst. 107 (2015) djv165, http://dx.doi.org/10.1093/jnci/djv165.
19. N. Azad, C.A. Zahnow, C.M. Rudin, S.B. Baylin, The future of epigenetic therapy in solid tumours: lessons from the past, Nat. Rev. Clin. Oncol. 10 (2013) 256.
20. P. Bertrand, Inside HDAC with HDAC inhibitors, Eur. J. Med. Chem. 45 (2010) 2095, http://dx.doi.org/10.1016/j.ejmech.2010.02.030.
21. S. Minucci, P.G. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat. Rev. Cancer 6 (2006) 38, http://dx.doi.org/10.1038/nrc1779.
22. X.-J. Yang, E. Seto, HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention, Oncogene 26 (2007) 5310.
23. P. Joshi, T.M. Greco, A.J. Guise, Y. Luo, F. Yu, A.I. Nesvizhskii, et al., The functional interactome landscape of the human histone deacetylase family, Mol. Syst. Biol. 9 (2013), http://dx.doi.org/10.1038/msb.2013.26.
24. K.J. Falkenberg, R.W. Johnstone, Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders, Nat. Rev. Drug Discov. 13 (2014) 673.
25. J.-H. Park, S.-H. Kim, M.-C. Choi, J. Lee, D.-Y. Oh, S.-A. Im, et al., Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors, Biochem. Biophys. Res. Commun. 368 (2008) 318, http://dx.doi.org/10.1016/j.bbrc.2008.01.056.
26. D. Li, S. Xie, Y. Ren, L. Huo, J. Gao, D. Cui, et al., Microtubule-associated deacetylase HDAC6 promotes angiogenesis by regulating cell migration in an EB1-dependent manner, Protein Cell. 2 (2011) 150, http://dx.doi.org/10.1007/s13238-011-1015-4.
27. D. Kaluza, J. Kroll, S. Gesierich, T. Yao, R.A. Boon, E. Hergenreider, et al., Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin, EMBO J. 30 (2011) 4142, http://dx.doi.org/10.1038/emboj.2011.298.
28. S.J. Choi, H. Lee, J. Kim, S.Y. Park, T. Kim, W. Lee, et al., HDAC6 regulates cellular viral RNA sensing by deacetylation of RIG-I, EMBO J. 35 (2016) 429, http://dx.doi.org/10.15252/embj.201592586.
29. A.G. Kazantsev, L.M. Thompson, Therapeutic application of histone deacetylase inhibitors for central nervous system disorders, Nat. Rev. Drug Discov. 7 (2008) 854, http://dx.doi.org/10.1038/nrd2681.
30. M. New, H. Olzscha, N.B. La Thangue, HDAC inhibitor-based therapies: can we interpret the code Cancer Epigenetics 6 (2012) 637, http://dx.doi.org/10.1016/j.molonc.2012.09.003.
31. J. Borrow, V.P. Stanton, J.M. Andresen, R. Becher, F.G. Behm, R.S.K. Chaganti, et al., The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein, Nat. Genet. 14 (1996) 33, http://dx.doi.org/10.1038/ng0996-33.
32. P.P. Pandolfi, F. Grignani, M. Alcalay, A. Mencarelli, A. Biondi, F. LoCoco, et al., Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties, Oncogene 6 (1991) 1285.
33. S. Zimmermann, F. Kiefer, M. Prudenziati, C. Spiller, J. Hansen, T. Floss, et al., Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice, Cancer Res. 67 (2007) 9047, http://dx.doi.org/10.1158/0008-5472.CAN-07-0312.
34. O. Witt, H.E. Deubzer, T. Milde, I. Oehme, HDAC family: what are the cancer relevant targets Cancer Lett. 277 (2009) 8, http://dx.doi.org/10.1016/j.canlet.2008.08.016.
35. C. Nervi, E. De Marinis, G. Codacci-Pisanelli, Epigenetic treatment of solid tumours: a review of clinical trials, Clin. Epigenetics 7 (2015) 1, http://dx.doi.org/10.1186/s13148-015-0157-2.
36. R.A. Juergens, J. Wrangle, F.P. Vendetti, S.C. Murphy, M. Zhao, B. Coleman, et al., Combination epigenetic therapy has efficacy in patients with refractory advanced nonesmall cell lung cancer, Cancer Discov. 1 (2011) 598, http://dx.doi.org/10.1158/2159-8290.CD-11-0214.
37. P.K. Mazur, A. Herner, S.S. Mello, M. Wirth, S. Hausmann, F.J. Sanchez-Rivera, et al., Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma, Nat. Med. 21 (2015) 1163.
38. H. Yuan, R. Marmorstein, Structural basis for sirtuin activity and inhibition, J. Biol. Chem. 287 (2012) 42428, http://dx.doi.org/10.1074/jbc.R112.372300.
39. A. Chalkiadaki, L. Guarente, The multifaceted functions of sirtuins in cancer, Nat. Rev. Cancer 15 (2015) 608.
40. A. Dereeper, V. Guignon, G. Blanc, S. Audic, S. Buffet, F. Chevenet, et al., Phylogeny.fr: robust phylogenetic analysis for the non-specialist, Nucleic Acids Res. 36 (2008) W465, http://dx.doi.org/10.1093/nar/gkn180.
41. J. Castresana, Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis, Mol. Biol. Evol. 17 (2000) 540.
42. S. Guindon, J.-F. Dufayard, V. Lefort, M. Anisimova, W. Hordijk, O. Gascuel, New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0, Syst. Biol. 59 (2010) 307, http://dx.doi.org/10.1093/sysbio/syq010.
43. M. Anisimova, O. Gascuel, Approximate likelihood-ratio test for branches: a fast, accurate, powerful alternative, Syst. Biol. 55 (2006) 539, http://dx.doi.org/10.1080/10635150600755453.
44. F. Chevenet, C. Brun, A.-L. Ba~nuls, B. Jacq, R. Christen, TreeDyn: towards dynamic graphics and annotations for analyses of trees, BMC Bioinforma. 7 (2006) 1, http://dx.doi.org/10.1186/1471-2105-7-439.
45. B. Barneda-Zahonero, M. Parra, Histone deacetylases and cancer, Cancer Epigenetics 6 (2012) 579, http://dx.doi.org/10.1016/j.molonc.2012.07.003.
46. D. Herman, K. Jenssen, R. Burnett, E. Soragni, S.L. Perlman, J.M. Gottesfeld, Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia, Nat. Chem. Biol. 2 (2006) 551, http://dx.doi.org/10.1038/nchembio815.
47. M. Rai, E. Soragni, K. Jenssen, R. Burnett, D. Herman, G. Coppola, et al., HDAC inhibitors correct frataxin deficiency in a friedreich ataxia mouse model, PLoS ONE 3 (2008) e1958, http://dx.doi.org/10.1371/journal.pone.0001958.
48. W. Fan, J. Huang, H. Xiao, Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of b-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma, Int. J. Clin. Exp. Med. 8 (2015) 3734.
49. R. Radhakrishnan, Y. Li, S. Xiang, F. Yuan, Z. Yuan, E. Telles, et al., Histone deacetylase 10 regulates dna mismatch repair and may involve the deacetylation of MutS Homolog 2, J. Biol. Chem. 290 (2015) 22795, http://dx.doi.org/10.1074/jbc.M114.612945.
50. Y. Li, L. Peng, E. Seto, Histone deacetylase 10 regulates the cell cycle G2/M phase transition via a novel Let-7eHMGA2ecyclin A2 pathway, Mol. Cell. Biol. 35 (2015) 3547, http://dx.doi.org/10.1128/MCB.00400-15.
51. G. Pinto, B. Shtaif, M. Phillip, G. Gat-Yablonski, Growth attenuation is associated with histone deacetylase 10-induced autophagy in the liver, J. Nutr. Biochem. 27 (2016) 171, http://dx.doi.org/10.1016/j.jnutbio.2015.08.031.
52. G. Estiu, E. Greenberg, C.B. Harrison, N.P. Kwiatkowski, R. Mazitschek, J.E. Bradner, et al., Structural origin of selectivity in class II-selective histone deacetylase inhibitors, J. Med. Chem. 51 (2008) 2898, http://dx.doi.org/10.1021/jm7015254.
53. M.K. Wambua, D.A. Nalawansha, A.T. Negmeldin, M.K.H. Pflum, Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design, J. Med. Chem. 57 (2014) 642, http://dx.doi.org/10.1021/jm401837e.
54. A.F. Abdel-Magid, Histone deacetylase 4 (HDAC4) inhibitors: a promising treatment for Huntington's disease, ACS Med. Chem. Lett. 4 (2013) 692, http://dx.doi.org/10.1021/ml4002216.
55. J.H. Kalin, J.A. Bergman, Development and therapeutic implications of selective histone deacetylase 6 inhibitors, J. Med. Chem. 56 (2013) 6297, http://dx.doi.org/10.1021/jm4001659.
56. R.W. Robey, A.R. Chakraborty, A. Basseville, V. Luchenko, J. Bahr, Z. Zhan, et al., Histone deacetylase inhibitors: emerging mechanisms of resistance, Mol. Pharm. 8 (2011) 2021, http://dx.doi.org/10.1021/mp200329f.
57. F. el Bahhaj, F.J. Dekker, N. Martinet, P. Bertrand, Delivery of epidrugs, Drug Discov. Today 19 (2014) 1337, http://dx.doi.org/10.1016/j.drudis.2014.03.017.
58. K.T. Andrews, A. Haque, M.K. Jones, HDAC inhibitors in parasitic diseases, Immunol. Cell Biol. 90 (2012) 66.
59. M. Marek, S. Kannan, A.-T. Hauser, M. Moraes Moureo, S. Caby, V. Cura, et al., Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni, PLoS Pathog. 9 (2013) e1003645, http://dx.doi.org/10.1371/journal.ppat.1003645.
60. T. Heimburg, A. Chakrabarti, J. Lancelot, M. Marek, J. Melesina, A.-T. Hauser, et al., Structure-based design and synthesis of novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of schistosomiasis, J. Med. Chem. 59 (2016) 2423, http://dx.doi.org/10.1021/acs.jmedchem.5b01478.
61. M.S. Finnin, J.R. Donigian, A. Cohen, V.M. Richon, R.A. Rifkind, P.A. Marks, et al., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors, Nature 401 (1999) 188, http://dx.doi.org/10.1038/43710.
62. R. Wu, S. Wang, N. Zhou, Z. Cao, Y. Zhang, A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions, J. Am. Chem. Soc. 132 (2010) 9471, http://dx.doi.org/10.1021/ja103932d.
63. R. Wu, Z. Lu, Z. Cao, Y. Zhang, Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel, J. Am. Chem. Soc. 133 (2011) 6110, http://dx.doi.org/10.1021/ja111104p.
64. S. Kalyaanamoorthy, Y.-P.P. Chen, Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors, J. Mol. Graph. Model. 44 (2013) 44, http://dx.doi.org/10.1016/j.jmgm.2013.05.002.
65. K. Chen, X. Zhang, Y.-D. Wu, O. Wiest, Inhibition and mechanism of HDAC8 revisited, J. Am. Chem. Soc. 136 (2014) 11636, http://dx.doi.org/10.1021/ja501548p.
66. F. Sister, M. Lucy Gantt, C. Decroos, M.S. Lee, L.E. Gullett, C.M. Bowman, D.W. Christianson, et al., General baseegeneral acid catalysis in human histone deacetylase 8, Biochem. (Mosc.) 55 (2016) 820, http://dx.doi.org/10.1021/acs.biochem.5b01327;
67. R.K. Singh, T. Suzuki, T. Mandal, N. Balsubramanian, M. Haldar, D.J. Mueller, J.A. Strode, G. Cook, S. Mallik, D.K. Srivastava, Thermodynamics of Binding of Structurally Similar Ligands to Histone Deacetylase 8 Sheds Light on Challenges in the Rational Design of Potent and Isozyme-Selective Inhibitors of the Enzyme, Biochemistry 53 (2014) 7445, http://dx.doi.org/10.1021/bi500711x.
68. C. Meyners, M.G.J. Baud, M.J. Fuchter, F.-J. Meyer-Almes, Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors, Anal. Biochem. 460 (2014) 39, http://dx.doi.org/10.1016/j.ab.2014.05.014.
69. D. Riester, C. Hildmann, A. Schwienhorst, F.-J. Meyer-Almes, Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer, Anal. Biochem. 362 (2007) 136, http://dx.doi.org/10.1016/j.ab.2006.12.019.
70. P.J. Tummino, R.A. Copeland, Residence time of receptor-ligand complexes and its effect on biological function, Biochem. (Mosc.) 47 (2008) 5481, http://dx.doi.org/10.1021/bi8002023.
71. A.M. Kral, N. Ozerova, J. Close, J. Jung, M. Chenard, J. Fleming, et al., Divergent kinetics differentiate the mechanism of action of two HDAC inhibitors, Biochem. (Mosc.) 53 (2014) 725, http://dx.doi.org/10.1021/bi400936h.
72. J. Pottel, E. Therrien, J.L. Gleason, N. Moitessier, Docking ligands into flexible and solvated macromolecules. 6. Development and application to the docking of HDACs and other zinc metalloenzymes inhibitors, J. Chem. Inf. Model 54 (2014) 254, http://dx.doi.org/10.1021/ci400550m.
73. Lei Zhang, Minyong Li, Lihui Zhang, Wenfang Xu, Discovering the binding modes of natural products with histone deacetylase 1, Med. Chem. 9 (2013) 126, http://dx.doi.org/10.2174/1573406411309010126.
74. U.S. Tambunan, N. Bramantya, A.A. Parikesit, In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC), BMC Bioinforma. 12 (2011) 1, http://dx.doi.org/10.1186/1471-2105-12-S13-S23.
75. U.S.F. Tambunan, E.K. Wulandari, Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculations and descriptor analysis, BMC Bioinforma. 11 (2010) 1, http://dx.doi.org/10.1186/1471-2105-11-S7-S16.
76. K.E. Cole, D.P. Dowling, M.A. Boone, A.J. Phillips, D.W. Christianson, Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases, J. Am. Chem. Soc. 133 (2011) 12474, http://dx.doi.org/10.1021/ja205972n.
77. M.B.A. Kunze, D.W. Wright, N.D. Werbeck, J. Kirkpatrick, P.V. Coveney, D.F. Hansen, Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8, J. Am. Chem. Soc. 135 (2013) 17862, http://dx.doi.org/10.1021/ja408184x.
78. C. Decroos, D.J. Clausen, B.E. Haines, O. Wiest, R.M. Williams, D.W. Christianson, Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8, Biochem. (Mosc.) 54 (2015) 2126, http://dx.doi.org/10.1021/acs.biochem.5b00010.
79. R.W. Bürli, C.A. Luckhurst, O. Aziz, K.L. Matthews, D. Yates, K.A. Lyons, et al., Design, synthesis, biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease, J. Med. Chem. 56 (2013) 9934, http://dx.doi.org/10.1021/jm4011884.
80. M. Lobera, K.P. Madauss, D.T. Pohlhaus, Q.G. Wright, M. Trocha, D.R. Schmidt, et al., Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group, Nat. Chem. Biol. 9 (2013) 319.
81. L. Silvestri, F. Ballante, A. Mai, G.R. Marshall, R. Ragno, Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction, J. Chem. Inf. Model 52 (2012) 2215, http://dx.doi.org/10.1021/ci300160y.
82. S. Thangapandian, S. John, S. Sakkiah, K.W. Lee, Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design, Eur. J. Med. Chem. 45 (2010) 4409, http://dx.doi.org/10.1016/j.ejmech.2010.06.024.
83. S.D. Micco, M.G. Chini, S. Terracciano, I. Bruno, R. Riccio, G. Bifulco, Structural basis for the design and synthesis of selective HDAC inhibitors, Bioorg. Med. Chem. 21 (2013) 3795, http://dx.doi.org/10.1016/j.bmc.2013.04.036.
84. X. Hou, J. Du, R. Liu, Y. Zhou, M. Li, W. Xu, et al., Enhancing the sensitivity of pharmacophore-based virtual screening by incorporating customized ZBG features: a case study using histone deacetylase 8, J. Chem. Inf. Model 55 (2015) 861, http://dx.doi.org/10.1021/ci500762z.
85. J.A. Day, S.M. Cohen, Investigating the selectivity of metalloenzyme inhibitors, J. Med. Chem. 56 (2013) 7997, http://dx.doi.org/10.1021/jm401053m.
86. M.M. Kemp, Q. Wang, J.H. Fuller, N. West, N.M. Martinez, E.M. Morse, et al., A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold, Bioorg. Med. Chem. Lett. 21 (2011) 4164, http://dx.doi.org/10.1016/j.bmcl.2011.05.098.
87. V. Patil, Q.H. Sodji, J.R. Kornacki, M. Mrksich, A.K. Oyelere, 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition, J. Med. Chem. 56 (2013) 3492, http://dx.doi.org/10.1021/jm301769u.
88. Q.H. Sodji, V. Patil, J.R. Kornacki, M. Mrksich, A.K. Oyelere, Synthesis and structureeactivity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors, J. Med. Chem. 56 (2013) 9969, http://dx.doi.org/10.1021/jm401225q.
89. H. Park, S. Kim, Y.E. Kim, S.-J. Lim, A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups, ChemMedChem. 5 (2010) 591, http://dx.doi.org/10.1002/cmdc.200900500.
90. J. Zhou, M. Li, N. Chen, S. Wang, H.-B. Luo, Y. Zhang, et al., Computational design of a time-dependent histone deacetylase 2 selective inhibitor, ACS Chem. Biol. 10 (2015) 687, http://dx.doi.org/10.1021/cb500767c.
91. L. Musso, R. Cincinelli, V. Zuco, F. Zunino, A. Nurisso, M. Cuendet, et al., Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors, Bioorg. Med. Chem. Lett. 25 (2015) 4457, http://dx.doi.org/10.1016/j.bmcl.2015.09.006.
92. M.M. Abdel-Atty, N.A. Farag, S.E. Kassab, R.A.T. Serya, K.A.M. Abouzid, Design, synthesis, 3D pharmacophore, QSAR, docking studies of carboxylic acid derivatives as histone deacetylase inhibitors and cytotoxic agents, Bioorg. Chem. 57 (2014) 65, http://dx.doi.org/10.1016/j.bioorg.2014.08.006.
93. J.M. Ontoria, S. Altamura, A. Di Marco, F. Ferrigno, R. Laufer, E. Muraglia, et al., Identification of Novel, selective, stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of hdac4 by small molecules as a novel approach for cancer therapy, J. Med. Chem. 52 (2009) 6782, http://dx.doi.org/10.1021/jm900555u.
94. H. Rajak, P. Kumar, P. Parmar, B.S. Thakur, R. Veerasamy, P.C. Sharma, et al., Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors, Eur. J. Med. Chem. 53 (2012) 390, http://dx.doi.org/10.1016/j.ejmech.2012.03.058.
95. S. Valente, D. Trisciuoglio, T. De Luca, A. Nebbioso, D. Labella, A. Lenoci, et al., 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells, J. Med. Chem. 57 (2014) 6259, http://dx.doi.org/10.1021/jm500303u.
96. E. Soragni, C. Xu, H.L. Plasterer, V. Jacques, J.R. Rusche, J.M. Gottesfeld, Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for friedreich ataxia, J. Child. Neurol. 27 (2012) 1164, http://dx.doi.org/10.1177/0883073812448533.
97. C.M. Marson, C.J. Matthews, E. Yiannaki, S.J. Atkinson, P.E. Soden, L. Shukla, et al., Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-Aminophenyl) benzamide binding unit, J. Med. Chem. 56 (2013) 6156, http://dx.doi.org/10.1021/jm400634n.
98. J.M. Guerra-Bubb, A.A. Bowers, W.B. Smith, R. Paranal, G. Estiu, O. Wiest, et al., Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs, Bioorg. Med. Chem. Lett. 23 (2013) 6025, http://dx.doi.org/10.1016/j.bmcl.2013.06.012.
99. B. Kim, H. Park, L.A. Salvador, P.E. Serrano, J.C. Kwan, S.L. Zeller, et al., Evaluation of class I HDAC isoform selectivity of largazole analogues, Bioorg. Med. Chem. Lett. 24 (2014) 3728, http://dx.doi.org/10.1016/j.bmcl.2014.07.006.
100. J.A. Souto, E. Vaz, I. Lepore, A.-C. Poppler, G. Franci, R.-Alvarez, et al., Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7-modified analogues, J. Med. Chem. 53 (2010) 4654, http://dx.doi.org/10.1021/jm100244y.
101. P. Bhansali, C.L. Hanigan, R.A. Casero, L.M.V. Tillekeratne, Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation, J. Med. Chem. 54 (2011) 7453, http://dx.doi.org/10.1021/jm200432a.
102. P. Bhansali, C.L. Hanigan, L. Perera, R.A.C. Jr., L.M.V. Tillekeratne, Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups, Eur. J. Med. Chem. 86 (2014) 528, http://dx.doi.org/10.1016/j.ejmech.2014.09.009.
103. L.A. Marcaurelle, E. Comer, S. Dandapani, J.R. Duvall, B. Gerard, S. Kesavan, et al., An aldol-based build/couple/pair strategy for the synthesis of mediumand large-sized rings: discovery of macrocyclic histone deacetylase inhibitors, J. Am. Chem. Soc. 132 (2010) 16962, http://dx.doi.org/10.1021/ja105119r.
104. S. Terracciano, S.D. Micco, G. Bifulco, P. Gallinari, R. Riccio, I. Bruno, Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222, Bioorg. Med. Chem. 18 (2010) 3252, http://dx.doi.org/10.1016/j.bmc.2010.03.022.
105. M.A. Hoque, M.N. Islam, M.S. Islam, T. Kato, N. Nishino, A. Ito, et al., Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors, Bioorg. Med. Chem. 22 (2014) 3850, http://dx.doi.org/10.1016/j.bmc.2014.06.029.
106. J.S. Villadsen, H.M. Stephansen, A.R. Maolanon, P. Harris, C.A. Olsen, Total Synthesis and Full Histone deacetylase inhibitory profiling of azumamides AeE as well as b2-epi-Azumamide E and b3-epi-Azumamide E, J. Med. Chem. 56 (2013) 6512, http://dx.doi.org/10.1021/jm4008449.
107. A.R. Maolanon, J.S. Villadsen, N.J. Christensen, C. Hoeck, T. Friis, P. Harris, et al., Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles, J. Med. Chem. 57 (2014) 9644, http://dx.doi.org/10.1021/jm501399d.
108. M.S. Islam, M.N. Islam, M.A. Hoque, N. Nishino, T. Kato, H.-J. Kim, et al., An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors, Bioorg. Chem. 59 (2015) 145, http://dx.doi.org/10.1016/j.bioorg.2015.02.009.
109. H. Sekizawa, K. Amaike, Y. Itoh, T. Suzuki, K. Itami, J. Yamaguchi, Late-Stage C-H coupling enables rapid identification of HDAC inhibitors: synthesis and evaluation of NCH-31 analogues, ACS Med. Chem. Lett. 5 (2014) 582-586.
110. F.E. Bahhaj, J. D-esir-e, C. Blanquart, N. Martinet, V. Zwick, C. Sim~oes-Pires, et al., Superacid and thiol-ene reactions for access to psammaplin analogues with HDAC inhibition activities, Tetrahedron. 70 (2014) 9702, http://dx.doi.org/10.1016/j.tet.2014.10.053.
111. T. Wang, M. Sepulveda, P. Gonzales, S. Gately, Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents, Bioorg. Med. Chem. Lett. 23 (2013) 4790, http://dx.doi.org/10.1016/j.bmcl.2013.07.001.
112. J. Amin, A. Puglisi, J. Clarke, J. Milton, M. Wang, R.M. Paranal, et al., A cyclodextrin-capped histone deacetylase inhibitor, Bioorg. Med. Chem. Lett. 23 (2013) 3346, http://dx.doi.org/10.1016/j.bmcl.2013.03.084.
113. Q. Sun, Y. Yao, C. Liu, H. Li, H. Yao, X. Xue, et al., Design, synthesis, biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry, Bioorg. Med. Chem. Lett. 23 (2013) 3295, http://dx.doi.org/10.1016/j.bmcl.2013.03.102.
114. W.-J. Huang, C.-C. Chen, S.-W. Chao, C.-C. Yu, C.-Y. Yang, J.-H. Guh, et al., Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors, Eur. J. Med. Chem. 46 (2011) 4042, http://dx.doi.org/10.1016/j.ejmech.2011.06.002.
115. L. Guandalini, M. Balliu, C. Cellai, M.V. Martino, A. Nebbioso, C. Mercurio, et al., Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring, Eur. J. Med. Chem. 66 (2013) 56, http://dx.doi.org/10.1016/j.ejmech.2013.05.017.
116. L. Han, L. Wang, X. Hou, H. Fu, W. Song, W. Tang, et al., Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo [d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors, Bioorg. Med. Chem. 22 (2014) 1529, http://dx.doi.org/10.1016/j.bmc.2014.01.045.
117. Y. Yao, C. Liao, Z. Li, Z. Wang, Q. Sun, C. Liu, et al., Design, synthesis, biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors, Eur. J. Med. Chem. 86 (2014) 639, http://dx.doi.org/10.1016/j.ejmech.2014.09.024.
118. Q. Tan, Z. Zhang, J. Hui, Y. Zhao, L. Zhu, Synthesis and anticancer activities of thieno [3,2-d]pyrimidines as novel HDAC inhibitors, Bioorg. Med. Chem. 22 (2014) 358, http://dx.doi.org/10.1016/j.bmc.2013.11.021.
119. W. Yang, L. Li, X. Ji, X. Wu, M. Su, L. Sheng, et al., Design, synthesis and biological evaluation of 4-anilinothieno [2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors, Bioorg. Med. Chem. 22 (2014) 6146, http://dx.doi.org/10.1016/j.bmc.2014.08.030.
120. G.D. Pompo, M. Salerno, D. Rotili, S. Valente, C. Zwergel, S. Avnet, et al., Novel histone deacetylase inhibitors induce growth arrest, apoptosis, differentiation in sarcoma cancer stem cells, J. Med. Chem. 58 (2015) 4073, http://dx.doi.org/10.1021/acs.jmedchem.5b00126.
121. T.T. Tung, D.T.K. Oanh, P.T.P. Dung, V.T.M. Hue, S.H. Park, B.W. Han, et al., New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents, Med. Chem. 9 (2013) 1051.
122. C. Salmi-Smail, A. Fabre, F. Dequiedt, A. Restouin, R. Castellano, S. Garbit, et al., Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity, J. Med. Chem. 53 (2010) 3038, http://dx.doi.org/10.1021/jm901358y.
123. R. He, Y. Chen, Y. Chen, A.V. Ougolkov, J.-S. Zhang, D.N. Savoy, et al., Synthesis and biological evaluation of Triazol-4-ylphenyl-Bearing histone deacetylase inhibitors as anticancer agents, J. Med. Chem. 53 (2010) 1347, http://dx.doi.org/10.1021/jm901667k.
124. F. Yang, T. Zhang, H. Wu, Y. Yang, N. Liu, A. Chen, et al., Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of bissubstituted aromatic amides bearing potent activities against tumor growth and metastasis, J. Med. Chem. 57 (2014) 9357, http://dx.doi.org/10.1021/jm5012148.
125. L. Marek, A. Hamacher, F.K. Hansen, K. Kuna, H. Gohlke, M.U. Kassack, et al., Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells, J. Med. Chem. 56 (2013) 427, http://dx.doi.org/10.1021/jm301254q.
126. F.K. Hansen, S.D.M. Sumanadasa, K. Stenzel, S. Duffy, S. Meister, L. Marek, et al., Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages, Eur. J. Med. Chem. 82 (2014) 204, http://dx.doi.org/10.1016/j.ejmech.2014.05.050.
127. S.E. Choi, S.V.W. Weerasinghe, M.K.H. Pflum, The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity, Bioorg. Med. Chem. Lett. 21 (2011) 6139, http://dx.doi.org/10.1016/j.bmcl.2011.08.027.
128. S.E. Choi, M.K.H. Pflum, The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position, Bioorg. Med. Chem. Lett. 22 (2012) 7084, http://dx.doi.org/10.1016/j.bmcl.2012.09.093.
129. M. Taddei, E. Cini, L. Giannotti, G. Giannini, G. Battistuzzi, D. Vignola, et al., Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors, Bioorg. Med. Chem. Lett. 24 (2014) 61, http://dx.doi.org/10.1016/j.bmcl.2013.11.072.
130. N.-H. Nam, T.L. Huong, D.T.M. Dung, P.T.P. Dung, D.T.K. Oanh, D. Quyen, et al., Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents, Eur. J. Med. Chem. 70 (2013) 477, http://dx.doi.org/10.1016/j.ejmech.2013.10.045.
131. J.-H. Lee, A. Mahendran, Y. Yao, L. Ngo, G. Venta-Perez, M.L. Choy, et al., Development of a histone deacetylase 6 inhibitor and its biological effects, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 15704, http://dx.doi.org/10.1073/pnas.1313893110.
132. K.V. Butler, J. Kalin, C. Brochier, G. Vistoli, B. Langley, A.P. Kozikowski, Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, Tubastatin A. J. Am. Chem. Soc. 132 (2010) 10842, http://dx.doi.org/10.1021/ja102758v.
133. J. Feng, H. Fang, X. Wang, Y. Jia, L. Zhang, J. Jiao, et al., Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer, Cancer Biol. Ther. 11 (2011) 477.
134. D.E. Olson, F.F. Wagner, T. Kaya, J.P. Gale, N. Aidoud, E.L. Davoine, et al., Discovery of the first histone deacetylase 6/8 dual inhibitors, J. Med. Chem. 56 (2013) 4816, http://dx.doi.org/10.1021/jm400390r.
135. X. Lin, W. Chen, Z. Qiu, L. Guo, W. Zhu, W. Li, et al., Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors, J. Med. Chem. 58 (2015) 2809, http://dx.doi.org/10.1021/jm502011f.
136. L. Zhang, Y. Zhang, C.J. Chou, E.S. Inks, X. Wang, X. Li, et al., Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities, ChemMedChem. 9 (2014) 638, http://dx.doi.org/10.1002/cmdc.201300297.
137. D.A. Rodrigues, G.-A. Ferreira-Silva, A.C.S. Ferreira, R.A. Fernandes, J.K. Kwee, C.M.R. Sant'Anna, et al., Design, synthesis, pharmacological evaluation of novel N-acylhydrazone derivatives as potent histone deacetylase 6/8 dual inhibitors, J. Med. Chem. 59 (2016) 655, http://dx.doi.org/10.1021/acs.jmedchem.5b01525.
138. C. Blackburn, C. Barrett, J. Chin, K. Garcia, K. Gigstad, A. Gould, et al., Potent histone deacetylase inhibitors derived from 4-(Aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform, J. Med. Chem. 56 (2013) 7201, http://dx.doi.org/10.1021/jm400385r.
139. G. Tang, J.C. Wong, W. Zhang, Z. Wang, N. Zhang, Z. Peng, et al., Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors, J. Med. Chem. 57 (2014) 8026, http://dx.doi.org/10.1021/jm5008962.
140. E. Marastoni, S. Bartoli, M. Berettoni, A. Cipollone, A. Ettorre, C.I. Fincham, et al., Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 1: hit identification, Bioorg. Med. Chem. Lett. 23 (2013) 4091, http://dx.doi.org/10.1016/j.bmcl.2013.05.053.
141. R. Cincinelli, L. Musso, G. Giannini, V. Zuco, M.D. Cesare, F. Zunino, et al., Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors, Eur. J. Med. Chem. 79 (2014) 251, http://dx.doi.org/10.1016/j.ejmech.2014.04.021.
142. B. Gopalan, T. Ponpandian, V. Kachhadia, K. Bharathimohan, R. Vignesh, V. Sivasudar, et al., Discovery of adamantane based highly potent HDAC inhibitors, Bioorg. Med. Chem. Lett. 23 (2013) 2532, http://dx.doi.org/10.1016/j.bmcl.2013.03.002.
143. C. Ning, Y. Bi, Y. He, W. Huang, L. Liu, Y. Li, et al., Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors, Bioorg. Med. Chem. Lett. 23 (2013) 6432, http://dx.doi.org/10.1016/j.bmcl.2013.09.051.
144. W.-J. Huang, C.-C. Chen, S.-W. Chao, S.-S. Lee, F.-L. Hsu, Y.-L. Lu, et al., Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase, ChemMedChem. 5 (2010) 598, http://dx.doi.org/10.1002/cmdc.200900494.
145. C.T. Chan, J. Qi, W. Smith, R. Paranol, R. Mazitschek, N. West, et al., Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects, Cancer Res. 74 (2014) 7475, http://dx.doi.org/10.1158/0008-5472.CAN-14-0197.
146. X. Li, E.S. Inks, X. Li, J. Hou, C.J. Chou, J. Zhang, et al., Discovery of the first NHydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity, J. Med. Chem. 57 (2014) 3324, http://dx.doi.org/10.1021/jm401877m.
147. H.-Y. Lee, A.-C. Tsai, M.-C. Chen, P.-J. Shen, Y.-C. Cheng, C.-C. Kuo, et al., Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells, J. Med. Chem. 57 (2014) 4009, http://dx.doi.org/10.1021/jm401899x.
148. W. Szymanski, M.E. Ourailidou, W.A. Velema, F.J. Dekker, B.L. Feringa, Lightcontrolled histone deacetylase (hdac) inhibitors: towards photopharmacological chemotherapy, Chem.dEur. J. 21 (2015) 16517, http://dx.doi.org/10.1002/chem.201502809.
149. M. Zhou, C. Ning, R. Liu, Y. He, N. Yu, Design, synthesis and biological evaluation of indeno [1,2-d]thiazole derivatives as potent histone deacetylase inhibitors, Bioorg. Med. Chem. Lett. 23 (2013) 3200, http://dx.doi.org/10.1016/j.bmcl.2013.04.004.
150. M.D. Shultz, X. Cao, C.H. Chen, Y.S. Cho, N.R. Davis, J. Eckman, et al., Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors, J. Med. Chem. 54 (2011) 4752, http://dx.doi.org/10.1021/jm200388e.
151. F. Thaler, M. Varasi, A. Abate, G. Carenzi, A. Colombo, C. Bigogno, et al., Synthesis and biological characterization of spiro [2H-(1,3)-benzoxazine-2,40-piperidine] based histone deacetylase inhibitors, Eur. J. Med. Chem. 64 (2013) 273, http://dx.doi.org/10.1016/j.ejmech.2013.03.061.
152. H. Wang, N. Yu, D. Chen, K.C.L. Lee, P.L. Lye, J.W.W. Chang, et al., Discovery of (2E)-3-2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile, J. Med. Chem., 54, 2011. 4694
153. F. Thaler, A. Colombo, A. Mai, R. Amici, C. Bigogno, R. Boggio, et al., Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors, J. Med. Chem. 53 (2010) 822, http://dx.doi.org/10.1021/jm901502p.
154. C.L. Fleming, T.D. Ashton, V. Gaur, S.L. McGee, F.M. Pfeffer, Improved synthesis and structural reassignment of MC1568: a class IIa selective HDAC inhibitor, J. Med. Chem. 57 (2014) 1132, http://dx.doi.org/10.1021/jm401945k.
155. T. Feng, H. Wang, H. Su, H. Lu, L. Yu, X. Zhang, et al., Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2), Bioorg. Med. Chem. 21 (2013) 5339, http://dx.doi.org/10.1016/j.bmc.2013.06.009.
156. T. Tashima, H. Murata, H. Kodama, Design and synthesis of novel and highlyactive pan-histone deacetylase (pan-HDAC) inhibitors, Bioorg. Med. Chem. 22 (2014) 3720, http://dx.doi.org/10.1016/j.bmc.2014.05.001.
157. J. Hou, Z. Li, Q. Fang, C. Feng, H. Zhang, W. Guo, et al., Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead, J. Med. Chem. 55 (2012) 3066, http://dx.doi.org/10.1021/jm201496g.
158. R.K. Singh, T. Mandal, N. Balasubramanian, G. Cook, D.K. Srivastava, Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors, Anal. Biochem. 408 (2011) 309, http://dx.doi.org/10.1016/j.ab.2010.08.040.
159. Y. Kong, M. Jung, K. Wang, S. Grindrod, A. Velena, S.A. Lee, et al., Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor, Mol. Cancer Ther. 10 (2011) 1591, http://dx.doi.org/10.1158/1535-7163.MCT-10-0779.
160. F. Hentschel, F. Sasse, T. Lindel, Fluorescent analogs of the marine natural product psammaplin A: synthesis and biological activity, Org. Biomol. Chem. 10 (2012) 7120, http://dx.doi.org/10.1039/C2OB25909E.
161. Q. Meng, Z. Liu, F. Li, J. Ma, H. Wang, Y. Huan, et al., An HDAC-Targeted Imaging Probe LBH589eCy5.5 for tumor detection and therapy evaluation, Mol. Pharm. 12 (2015) 2469, http://dx.doi.org/10.1021/acs.molpharmaceut.5b00167.
162. R.-R. Ye, Z.-F. Ke, C.-P. Tan, L. He, L.-N. Ji, Z.-W. Mao, Histone-deacetylasetargeted fluorescent ruthenium(II) polypyridyl complexes as potent anticancer agents, Chem. e Eur. J. 19 (2013) 10160, http://dx.doi.org/10.1002/chem.201300814.
163. R. Baba, Y. Hori, S. Mizukami, K. Kikuchi, Development of a fluorogenic probe with a transesterification switch for detection of histone deacetylase activity, J. Am. Chem. Soc. 134 (2012) 14310, http://dx.doi.org/10.1021/ja306045j.
164. B.M. Zeglis, N. Pillarsetty, V. Divilov, R.A. Blasberg, J.S. Lewis, The synthesis and evaluation of N1-(4-(2-[18F]-FESAHA), A PET radiotracer designed for the delineation of histone deacetylase expression in cancer, Nucl. Med. Biol. 38 (2011) 683, http://dx.doi.org/10.1016/j.nucmedbio.2010.12.008.
165. Q. Meng, F. Li, S. Jiang, Z. Li, Novel 64Cu-Labeled CUDC-101 for in vivo PET imaging of histone deacetylases, ACS Med. Chem. Lett. 4 (2013) 858, http://dx.doi.org/10.1021/ml400191z.
166. Y. Wang, Y.-L. Zhang, K. Hennig, J.P. Gale, Y. Hong, A. Cha, et al., Class I HDAC imaging using [3H]CI-994 autoradiography, Epigenetics 8 (2013) 756, http://dx.doi.org/10.4161/epi.25202.
167. C. Wang, T.E. Eessalu, V.N. Barth, C.H. Mitch, F.F. Wagner, Y. Hong, et al., Design, synthesis, evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain, Am. J. Nucl. Med. Mol. Imaging 4 (2014) 29.
168. S. Clive, M. Woo, T. Nydam, L. Kelly, M. Squier, M. Kagan, Characterizing the disposition, metabolism, excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients, Cancer Chemother. Pharmacol. 70 (2012) 513, http://dx.doi.org/10.1007/s00280-012-1940-9.
169. Y.J. Seo, L. Muench, A. Reid, J. Chen, Y. Kang, J.M. Hooker, et al., Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain, Bioorg. Med. Chem. Lett. 23 (2013) 6700, http://dx.doi.org/10.1016/j.bmcl.2013.10.038.
170. Y.J. Seo, Y. Kang, L. Muench, A. Reid, S. Caesar, L. Jean, et al., Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors, ACS Chem. Neurosci. 5 (2014) 588, http://dx.doi.org/10.1021/cn500021p.
171. S.W. Kim, J.M. Hooker, N. Otto, K. Win, L. Muench, C. Shea, et al., Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET, Nucl. Med. Biol. 40 (2013) 912, http://dx.doi.org/10.1016/j.nucmedbio.2013.06.007.
172. X. Zhang, B. Bao, X. Yu, L. Tong, Y. Luo, Q. Huang, et al., The discovery and optimization of novel dual inhibitors of topoisomerase ii and histone deacetylase, Bioorg. Med. Chem. 21 (2013) 6981, http://dx.doi.org/10.1016/j.bmc.2013.09.023.
173. W. Guerrant, V. Patil, J.C. Canzoneri, A.K. Oyelere, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors, J. Med. Chem. 55 (2012) 1465, http://dx.doi.org/10.1021/jm200799p.
174. B.E. Gryder, M.J. Akbashev, M.K. Rood, E.D. Raftery, W.M. Meyers, P. Dillard, et al., Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors, ACS Chem. Biol. 8 (2013) 2550, http://dx.doi.org/10.1021/cb400542w.
175. B.E. Gryder, M.K. Rood, K.A. Johnson, V. Patil, E.D. Raftery, L.-P.D. Yao, et al., Histone deacetylase inhibitors equipped with estrogen receptor modulation activity, J. Med. Chem. 56 (2013) 5782, http://dx.doi.org/10.1021/jm400467w.
176. H.K. Patel, M.I. Siklos, H. Abdelkarim, E.L. Mendonca, A. Vaidya, P.A. Petukhov, et al., A chimeric SERMehistone deacetylase inhibitor approach to breast cancer therapy, ChemMedChem. 9 (2014) 602, http://dx.doi.org/10.1002/cmdc.201300270.
177. X. Cai, H.-X. Zhai, J. Wang, J. Forrester, H. Qu, L. Yin, et al., Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, HER2 inhibitor for the treatment of cancer, J. Med. Chem. 53 (2010) 2000, http://dx.doi.org/10.1021/jm901453q.
178. S. Mahboobi, A. Sellmer, M. Winkler, E. Eichhorn, H. Pongratz, T. Ciossek, et al., Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (egfr)